ALK and non-small cell lung carcinoma: Moreover, the second-generation ALK-TKIs ceritinib, alectinib, and brigatinib, and the third-generation ALK TKI lorlatinib, showed an enhanced effect on the treatment of ALK-rearranged NSCLC compared with crizotinib.